Kodiak Sciences (KOD)

• Market cap: $377M
• 1 day: -6.15%
• 5 days: -11.81%
• 1 month: -19.17%
• 3 months: 117.27%
• 6 months: 138.21%
• Year to date: -16.82%
• 1 year: 120.62%
• 5 years: -89.15%
• 10 years: -29.43%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.

Employees: 108

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

8% more capital invested

Capital invested by funds: $95.2M [Q2] → $103M (+$7.83M) [Q3]

2.13% less ownership

Funds ownership: 77.07% [Q2] → 74.94% (-2.13%) [Q3]

8% less funds holding

Funds holding: 105 [Q2] → 97 (-8) [Q3]

10% less repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 29

28% less call options, than puts

Call options by funds: $31K | Put options by funds: $43K

33% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 18

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $3 58% downside
• Avg. target: $9 26% upside
• High target: $20 179% upside

3 analyst ratings

• positive: 1 33%
• neutral: 1 33%
• negative: 1 33%

Jefferies Michael Yee 10% 1-year accuracy 1 / 10 met price target	179% upside $20	Buy Upgraded	9 Dec 2024
Barclays Gena Wang 16% 1-year accuracy 5 / 31 met price target	44% downside $4	Underweight Maintained	15 Nov 2024
HC Wainwright & Co. Matthew Caufield 19% 1-year accuracy 10 / 52 met price target	58% downside $3	Neutral Reiterated	15 Nov 2024